Literature DB >> 19594195

Tobacco smoking in individuals with attention-deficit hyperactivity disorder: epidemiology and pharmacological approaches to cessation.

Kevin M Gray1, Himanshu P Upadhyaya.   

Abstract

The co-occurrence of attention-deficit hyperactivity disorder (ADHD) and nicotine dependence is common. Individuals with ADHD are more likely to initiate smoking and become dependent on nicotine than their non-ADHD counterparts, and recent evidence suggests that they may have more difficulty quitting smoking. Little is known about how to best approach treating these co-morbidities to optimize clinical outcome. Clinicians treating individuals with either ADHD or nicotine dependence should be aware of their common co-occurrence and the need to address both in treatment. This review of ADHD and nicotine dependence provides an overview of relevant epidemiology, bidirectional interactions and implications for pharmacological and adjunctive psychosocial treatment. Incorporating the current evidence base and their clinical experience, the authors propose a stepwise approach to treating patients with co-morbid ADHD and nicotine dependence. Given the potential for ADHD symptoms to interfere with smoking cessation success, the first priority is to stabilize ADHD. The first-line pharmacological approach should be a long-acting psychostimulant. Upon ADHD stabilization, motivational techniques should be used to encourage readiness for a smoking cessation attempt. In the context of behavioural cessation interventions sensitive to the patient's needs and developmental stage, pharmacological intervention targeting smoking cessation may be initiated. The authors recommend varenicline as a first-line agent, given its superior effect size among available medication treatments. Symptoms of ADHD, as well as nicotine withdrawal and craving symptoms, should be monitored closely during the cessation attempt, and adjustments to therapy should be considered if warranted. The authors conclude that, while current treatments may potentially be effective for co-morbid ADHD and nicotine dependence, further research is needed to parse the complex associations between these disorders and prospectively study combined treatments.

Entities:  

Mesh:

Year:  2009        PMID: 19594195      PMCID: PMC2782603          DOI: 10.2165/00023210-200923080-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  58 in total

1.  A meta-analysis of teen cigarette smoking cessation.

Authors:  Steve Sussman; Ping Sun; Clyde W Dent
Journal:  Health Psychol       Date:  2006-09       Impact factor: 4.267

2.  Nicotine effects on adults with attention-deficit/hyperactivity disorder.

Authors:  E D Levin; C K Conners; E Sparrow; S C Hinton; D Erhardt; W H Meck; J E Rose; J March
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

3.  Personality differences associated with smoking experimentation among adolescents with and without comorbid symptoms of ADHD.

Authors:  Kenneth P Tercyak; Janet Audrain-McGovern
Journal:  Subst Use Misuse       Date:  2003-12       Impact factor: 2.164

4.  Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study.

Authors:  F Joseph McClernon; Scott H Kollins; Avery M Lutz; David P Fitzgerald; Desiree W Murray; Christina Redman; Jed E Rose
Journal:  Psychopharmacology (Berl)       Date:  2007-11-25       Impact factor: 4.530

5.  Patterns of temperament and character in a clinical sample of Korean children with attention-deficit hyperactivity disorder.

Authors:  Soo-Churl Cho; Jun-Won Hwang; In-Kyoon Lyoo; Hee-Jung Yoo; Boong-Nyun Kin; Jae-Won Kim
Journal:  Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.188

Review 6.  Nicotine and nicotinic receptor involvement in neuropsychiatric disorders.

Authors:  Paul Newhouse; Abhay Singh; Alexandra Potter
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

7.  Nicotine and brain-stimulation reward: interactions with morphine, amphetamine and pimozide.

Authors:  D Huston-Lyons; M Sarkar; C Kornetsky
Journal:  Pharmacol Biochem Behav       Date:  1993-10       Impact factor: 3.533

8.  No increase in long-term risk for nicotine use disorders after treatment with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD): evidence from a non-randomised retrospective study.

Authors:  M Huss; F Poustka; G Lehmkuhl; U Lehmkuhl
Journal:  J Neural Transm (Vienna)       Date:  2008-02-08       Impact factor: 3.575

9.  Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood.

Authors:  Bernard F Fuemmeler; Scott H Kollins; F Joseph McClernon
Journal:  J Pediatr Psychol       Date:  2007-06-30

10.  Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.

Authors:  H-J Aubin; A Bobak; J R Britton; C Oncken; C B Billing; J Gong; K E Williams; K R Reeves
Journal:  Thorax       Date:  2008-02-08       Impact factor: 9.139

View more
  11 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation.

Authors:  L Cinnamon Bidwell; Hollis C Karoly; Kent E Hutchison; Angela D Bryan
Journal:  Drug Alcohol Depend       Date:  2017-07-18       Impact factor: 4.492

3.  Attention-deficit/hyperactivity disorder (ADHD) symptoms, craving to smoke, and tobacco withdrawal symptoms in adult smokers with ADHD.

Authors:  Ivan Berlin; Mei-Chen Hu; Lirio S Covey; Theresa Winhusen
Journal:  Drug Alcohol Depend       Date:  2012-02-23       Impact factor: 4.492

4.  Smoking cessation treatment for adolescents.

Authors:  Julie P Karpinski; Erin M Timpe; Lisa Lubsch
Journal:  J Pediatr Pharmacol Ther       Date:  2010-10

5.  ADHD as a risk factor for early onset and heightened adult problem severity of illicit substance use: an accelerated gateway model.

Authors:  Eugene M Dunne; Lauren E Hearn; Jonathan J Rose; William W Latimer
Journal:  Addict Behav       Date:  2014-07-10       Impact factor: 3.913

6.  Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate.

Authors:  Lirio S Covey; Mei-Chen Hu; Judith Weissman; Ivana Croghan; Lenard Adler; Theresa Winhusen
Journal:  Nicotine Tob Res       Date:  2011-06-07       Impact factor: 4.244

Review 7.  Attention-deficit/hyperactivity disorder and adverse health outcomes.

Authors:  Joel T Nigg
Journal:  Clin Psychol Rev       Date:  2012-12-07

Review 8.  Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Authors:  José Pérez de los Cobos; Núria Siñol; Víctor Pérez; Joan Trujols
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

9.  Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder.

Authors:  Sydney Osland; Lauren Hirsch; Tamara Pringsheim
Journal:  BJPsych Open       Date:  2017-05-19

Review 10.  Concurrent Disorder Management Guidelines. Systematic Review.

Authors:  Syune Hakobyan; Sara Vazirian; Stephen Lee-Cheong; Michael Krausz; William G Honer; Christian G Schutz
Journal:  J Clin Med       Date:  2020-07-28       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.